Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.

Just approved In US for chronic kidney disease in patients with type 2 diabetes, Kerendia is going to be an important new treatment option, according to Bayer pharma head Stefan Oelrich, who was speaking as the Leverkusen-headquartered group unveiled a decent set of sales figures for the second quarter.

Regeneron's antibody cocktail gets emergency authorization for post-exposure prophylaxis from the US FDA. Daewoong's camostat shows efficacy in older patients in South Korean trial. 

ICER discussion on the health benefit of several upcoming drugs for atopic dermatitis, including several JAK inhibitors, touches on safety concerns and the likelihood that increased competition will open the door to higher list prices and rebating in the class.